Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Lineage Cell Therapeutics (LCTX) Shares Outstanding (Diluted Average): 2014-2025

Historic Shares Outstanding (Diluted Average) for Lineage Cell Therapeutics (LCTX) over the last 11 years, with Sep 2025 value amounting to $228.9 million.

  • Lineage Cell Therapeutics' Shares Outstanding (Diluted Average) rose 21.19% to $228.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $228.9 million, marking a year-over-year increase of 21.19%. This contributed to the annual value of $200.2 million for FY2024, which is 15.94% up from last year.
  • According to the latest figures from Q3 2025, Lineage Cell Therapeutics' Shares Outstanding (Diluted Average) is $228.9 million, which was up 0.22% from $228.4 million recorded in Q2 2025.
  • Lineage Cell Therapeutics' Shares Outstanding (Diluted Average)'s 5-year high stood at $228.9 million during Q3 2025, with a 5-year trough of $158,725 in Q1 2021.
  • Over the past 3 years, Lineage Cell Therapeutics' median Shares Outstanding (Diluted Average) value was $188.8 million (recorded in 2024), while the average stood at $193.8 million.
  • The largest annual percentage gain for Lineage Cell Therapeutics' Shares Outstanding (Diluted Average) in the last 5 years was 108,639.10% (2021), contrasted with its biggest fall of 99.89% (2021).
  • Over the past 5 years, Lineage Cell Therapeutics' Shares Outstanding (Diluted Average) (Quarterly) stood at $167.6 million in 2021, then rose by 1.29% to $169.8 million in 2022, then grew by 1.69% to $172.7 million in 2023, then rose by 15.94% to $200.2 million in 2024, then increased by 21.19% to $228.9 million in 2025.
  • Its Shares Outstanding (Diluted Average) stands at $228.9 million for Q3 2025, versus $228.4 million for Q2 2025 and $226.1 million for Q1 2025.